<qa>  What is the risk of bleeding?- Evidence or history of bleeding diathesis greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-1 or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhagebleeding event grade 3 within 4 weeks prior to registration; note: patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks of low molecular weight heparin; therapeutic Coumadin and aspirin doses 325 mg daily are not allowed 